Deferasirox has strong anti-leukemia activity but may antagonize theanti-leukemia effect of doxorubicin

References

• Dixon SJ, Stockwell BR. The role of iron and reactive oxygen species in cell death. Nat Chem Biol. 2014;10:9–17.
   PubMed Web of Science ®Google Scholar
• Stevens RG, Graubard BI, Micozzi MS, et al. Moderate elevation of body iron level and increased risk of cancer occurrence and death. Int J Cancer. 1994;56:364–369.
   PubMed Web of Science ®Google Scholar
• Stevens RG, Jones DY, Micozzi MS, et al. Body iron stores and the risk of cancer. N Engl J Med. 1988; 319:1047–1052.
   PubMed Web of Science ®Google Scholar
• Bradbear RA, Bain C, Siskind V, et al. Cohort study of internal malignancy in genetic hemochromatosis and other chronic nonalcoholic liver diseases. J. Natl Cancer Inst 1985;75:81–84.
   PubMed Web of Science ®Google Scholar
• Hsing AW, McLaughlin JK, Olsen JH, et al. Cancer risk following primary hemochromatosis: a population-based cohort study in Denmark. Int J Cancer. 1995;60:160–162.
   PubMed Web of Science ®Google Scholar
• Osborne NJ, Gurrin LC, Allen KJ, et al. HFE C282Y homozygotes are at increased risk of breast and colorectal cancer. Hepatology. 2010;51:1311–1318.
   PubMed Web of Science ®Google Scholar
• Toyokuni S. Role of iron in carcinogenesis: cancer as a ferrotoxic disease. Cancer Sci. 2009;100:9–16.
   PubMed Web of Science ®Google Scholar
• Zacharski LR, Chow BK, Howes PS, et al. Decreased cancer risk after iron reduction in patients with peripheral arterial disease: results from a randomized trial. J Natl Cancer Inst. 2008;100:996–1002.
   PubMed Web of Science ®Google Scholar
• Ba Q, Hao M, Huang H, et al. Iron deprivation suppresses hepatocellular carcinoma growth in experimental studies. Clin Cancer Res. 2011;17:7625–7633.
   PubMed Web of Science ®Google Scholar
• Siriwardana G, Seligman PA. Iron depletion results in Src kinase inhibition with associated cell cycle arrest in neuroblastoma cells. Physiol Rep. 2015;3:e12341.
   PubMedGoogle Scholar
• Ford SJ, Obeidy P, Lovejoy DB, et al. Deferasirox (ICL670A) effectively inhibits oesophageal cancer growth in vitro and in vivo. Br J Pharmacol. 2013;168:1316–1328.
   PubMed Web of Science ®Google Scholar
• Lescoat G, Chantrel-Groussard K, Pasdeloup N, et al. Antiproliferative and apoptotic effects in rat and human hepatoma cell cultures of the orally active iron chelator ICL670 compared to CP20: a possible relationship with polyamine metabolism. Cell Prolif. 2007;40:755–767.
   PubMed Web of Science ®Google Scholar
• Ohyashiki JH, Kobayashi C, Hamamura R, et al. The oral iron chelator deferasirox represses signaling through the mTOR in myeloid leukemia cells by enhancing expression of REDD1. Cancer Sci. 2009;100:970–977.
   PubMed Web of Science ®Google Scholar
• Messa E, Carturan S, Maffè, et al. Deferasirox is a powerful NF-κB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging. Haematologica. 2010;95:1308–1316.
   PubMed Web of Science ®Google Scholar
• Gattermann N, Finelli C, Della Porta M, et al. Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes. Haematologica. 2012;97:1364–1371.
   PubMed Web of Science ®Google Scholar
• Fukushima T, Kawabata H, Nakamura T, et al. Iron chelation therapy with deferasirox induced complete remission in a patient with chemotherapy-resistant acute monocytic leukemia. Anticancer Res. 2011;31:1741–1744.
   PubMed Web of Science ®Google Scholar
• Bendova P, Mackova E, Haskova P, et al. Comparison of clinically used and experimental iron chelators for protection against oxidative stress-induced cellular injury. Chem Res Toxicol. 2010;23:1105–1114.
   PubMed Web of Science ®Google Scholar
• Prus E, Fibach E. Flow cytometry measurement of the labile iron pool in human hematopoietic cells. Cytometry A. 2008;73:22–27.
   PubMed Web of Science ®Google Scholar
• Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 2006;58:621–681.
   PubMed Web of Science ®Google Scholar
• Minotti G, Menna P, Salvatorelli E, et al. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev. 2004;56:185–229.
   PubMed Web of Science ®Google Scholar
• Heinemann V, Estey E, Keating MJ, et al. Patient-specific dose rate for continuous infusion high-dose cytarabine in relapsed acute myelogenous leukemia. J Clin Oncol. 1989;7:622–628.
   PubMed Web of Science ®Google Scholar
• Chang F, Steelman LS, Lee JT, et al. Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention. Leukemia. 2003;17:1263–1293.
   PubMed Web of Science ®Google Scholar
• McCubrey JA, Steelman LS, Chappell WH, et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta. 2007;1773:1263–1284.
   PubMed Web of Science ®Google Scholar
• Nisbet-Brown E, Olivieri NF, Giardina PJ, et al. Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet. 2003;361:1597–1602.
   PubMed Web of Science ®Google Scholar
• Lamba JK. Genetic factors influencing cytarabine therapy. Pharmacogenomics. 2019;10:1657–1674.
   Web of Science ®Google Scholar
• Ohta T, Hori H, Ogawa M, et al. Impact of cytidine deaminase activity on intrinsic resistance to cytarabine in carcinoma cells. Oncol Rep. 2004;12:1115–1120.
   PubMed Web of Science ®Google Scholar
• Barnes C, Smith HC. Apolipoprotein B mRNA editing in vitro is a zinc-dependent process. Biochem Biophys Res Commun. 1993;197:1410–1414.
   PubMed Web of Science ®Google Scholar
• Vincenzetti S, Cambi A, Neuhard J, et al. Recombinant human cytidine deaminase: expression, purification, and characterization. Protein Expr Purif. 1996;8:247–253.
   PubMed Web of Science ®Google Scholar
• Erdoğan E, Canatan D, Ormeci AR, et al. The effects of chelators on zinc levels in patients with thalassemia major. J Trace Elem Med Biol. 2013; 27:109–111.
   PubMed Web of Science ®Google Scholar
• Lui GY, Obeidy P, Ford SJ, et al. The iron chelator, deferasirox, as a novel strategy for cancer treatment: oral activity against human lung tumor xenografts and molecular mechanism of action. Mol Pharmacol. 2013;83:179–190.
   PubMed Web of Science ®Google Scholar
• Tataranni T, Agriesti F, Mazzoccoli C, et al. The iron chelator deferasirox affects redox signalling in haematopoietic stem/progenitor cells. Br J Haematol. 2015;170:236–246.
   PubMed Web of Science ®Google Scholar